Abnormalities of the αβ T-cell receptor repertoire in advanced myelodysplastic syndrome

Experimental Hematology

Volumn 38, Issue 3, 2010, Pages 202-212

  Campregher, Paulo V ^a   Srivastava, Santosh K ^a   Deeg, H Joachim ^a,b   Robins, Harlan S ^a   Warren, Edus H ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYTOTOXIC AGENT; GROWTH FACTOR; LENALIDOMIDE; ONCOPROTEIN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; THALIDOMIDE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; WILM TUMOR 1 PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CELL COUNT; CLASSIFICATION ALGORITHM; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOBLAST; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; WORLD HEALTH ORGANIZATION; ADOLESCENT; ALGORITHM; BONE MARROW CELL; CLASSIFICATION; COMPLEMENTARITY DETERMINING REGION; GENETICS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BONE MARROW CELLS; CLUSTER ANALYSIS; COMPLEMENTARITY DETERMINING REGIONS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 76749142133     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.12.004     Document Type: Article

References (50)

1. Jonasova A., Neuwirtova R., Cermak J., et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 100 (1998) 304-309
2. Shimamoto T., Tohyama K., Okamoto T., et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res 27 (2003) 783-788
3. Molldrem J.J., Caples M., Mavroudis D., Plante M., Young N.S., and Barrett A.J. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99 (1997) 699-705
4. Molldrem J.J., Jiang Y.Z., Stetler-Stevenson M., Mavroudis D., Hensel N., and Barrett A.J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102 (1998) 1314-1322
5. Saunthararajah Y., Nakamura R., Nam J.M., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100 (2002) 1570-1574
6. Kochenderfer J.N., Kobayashi S., Wieder E.D., Su C., and Molldrem J.J. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 100 (2002) 3639-3645
7. Killick S.B., Mufti G., Cavenagh J.D., et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 120 (2003) 679-684
8. Yazji S., Giles F.J., Tsimberidou A.M., et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 17 (2003) 2101-2106
9. Stadler M., Germing U., Kliche K.O., et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18 (2004) 460-465
10. Broliden P.A., Dahl I.M., Hast R., et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 91 (2006) 667-670
11. Deeg H.J., Jiang P.Y., Holmberg L.A., Scott B., Petersdorf E.W., and Appelbaum F.R. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res 28 (2004) 1177-1180
12. Smith M.A., and Smith J.G. The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res 15 (1991) 597-601
13. Sugawara T., Endo K., Shishido T., et al. T cell-mediated inhibition of erythropoiesis in myelodysplastic syndromes. Am J Hematol 41 (1992) 304-305
14. Baumann I., Scheid C., Koref M.S., Swindell R., Stern P., and Testa N.G. Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic syndrome. Exp Hematol 30 (2002) 1405-1411
15. Sloand E.M., Mainwaring L., Fuhrer M., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 106 (2005) 841-851
16. Epperson D.E., Nakamura R., Saunthararajah Y., Melenhorst J., and Barrett A.J. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 25 (2001) 1075-1083
17. Wlodarski M.W., Gondek L.P., Nearman Z.P., et al. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood 108 (2006) 2632-2641
18. Kook H., Zeng W., Guibin C., Kirby M., Young N.S., and Maciejewski J.P. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 29 (2001) 1270-1277
19. Melenhorst J.J., Eniafe R., Follmann D., Nakamura R., Kirby M., and Barrett A.J. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 119 (2002) 97-105
20. Epling-Burnette P.K., Painter J.S., Rollison D.E., et al. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia 21 (2007) 659-667
21. Fozza C., Contini S., Galleu A., et al. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol 37 (2009) 947-955
22. Posnett D.N., Sinha R., Kabak S., and Russo C. Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy". J Exp Med 179 (1994) 609-618
23. Schwab R., Szabo P., Manavalan J.S., et al. Expanded CD4+ and CD8+ T cell clones in elderly humans. J Immunol 158 (1997) 4493-4499
24. Naylor K., Li G., Vallejo A.N., et al. The influence of age on T cell generation and TCR diversity. J Immunol 174 (2005) 7446-7452
25. Khan N., Shariff N., Cobbold M., et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 169 (2002) 1984-1992
26. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
27. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
28. Onida F., Kantarjian H.M., Smith T.L., et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 99 (2002) 840-849
29. Barragan E., Cervera J., Bolufer P., et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 89 (2004) 926-933
30. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25 (2001) 402-408
31. Akatsuka Y., Martin E.G., Madonik A., Barsoukov A.A., and Hansen J.A. Rapid screening of T-cell receptor (TCR) variable gene usage by multiplex PCR: application for assessment of clonal composition. Tissue Antigens 53 (1999) 122-134
32. Peggs K.S., Verfuerth S., D'Sa S., Yong K., and Mackinnon S. Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation. Br J Haematol 120 (2003) 154-165
33. McHeyzer-Williams M.G., and Davis M.M. Antigen-specific development of primary and memory T cells in vivo. Science 268 (1995) 106-111
34. Xu R., and Wunsch II D. Survey of clustering algorithms. IEEE Trans Neural Netw 16 (2005) 645-678
35. Kook H., Risitano A.M., Zeng W., et al. Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood 99 (2002) 3668-3675
36. Sloand E.M., Kim S., Fuhrer M., et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 100 (2002) 4427-4432
37. Miqueu P., Guillet M., Degauque N., Dore J.C., Soulillou J.P., and Brouard S. Statistical analysis of CDR3 length distributions for the assessment of T and B cell repertoire biases. Mol Immunol 44 (2007) 1057-1064
38. Ma X., Does M., Raza A., and Mayne S.T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109 (2007) 1536-1542
39. Rollison D.E., Howlader N., Smith M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112 (2008) 45-52
40. Bernell P., Jacobsson B., Nordgren A., and Hast R. Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology. Leukemia 10 (1996) 662-668
41. Tamaki H., Ogawa H., Ohyashiki K., et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13 (1999) 393-399
42. Cilloni D., Gottardi E., Messa F., et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 21 (2003) 1988-1995
43. Elisseeva O.A., Oka Y., Tsuboi A., et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99 (2002) 3272-3279
44. Gaiger A., Reese V., Disis M.L., and Cheever M.A. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96 (2000) 1480-1489
45. Wu F., Oka Y., Tsuboi A., et al. Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia 19 (2005) 268-274
46. Rezvani K., Yong A.S., Mielke S., et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111 (2008) 236-242
47. Holsinger AL, Ramakrishnan A, Storer B, et al. Therapy of myelodysplastic syndrome (MDS) with azacitidine given in combination with etanercept: a phase II study. Blood (ASH Annual Meeting Abstracts). 2007;110:Abstract 1452.
48. Sigalotti L., Altomonte M., Colizzi F., et al. 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. Blood 101 (2003) 4644-4646
49. Oki Y., Jelinek J., Shen L., Kantarjian H.M., and Issa J.P. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 111 (2008) 2382-2384
50. Holt R.A., and Jones S.J. The new paradigm of flow cell sequencing. Genome Res 18 (2008) 839-846